Cambridge Epigenetix relocates to Chesterford Research Park to accelerate growth

PRESS RELEASE

Cambridge, September 05, 2017:  Chesterford Research Park is delighted to confirm the arrival of Cambridge Epigenetix on site. The organisation, whose mission is to harness the power of epigenetics to develop the next generation of diagnostics and therapeutics, has moved into the 15,000 sq ft Trinity Building at the Park.

Spun-out of the University of Cambridge in 2012, Cambridge Epigenetix was founded by Professor Sir Shankar Balasubramanian (co-inventor of the Solexa/Illumina sequencing-by-synthesis platform) and Dr Bobby Yerramilli-Rao to commercialise its founding technology, oxidative bisulfite sequencing (oxBS-Seq), which has enabled researchers to prove the link between epigenetic DNA modifications and disease.

The move to Chesterford unites the current team under one roof and will facilitate the rapid growth of the organisation as it focuses on the utilisation of its proprietary epigenetic discovery platforms to develop improved diagnostic tests, both in house and in partnership with leading biopharma companies.

Dr Jason Mellad, CEO, Cambridge Epigenetix commented of the move: “We are committed to delivering on the promise of epigenetics to improve human health. The move to Chesterford Research Park is a vital component of our strategy, providing us with state-of-the-art facilities and importantly the space to grow as we expand our biomarker discovery capabilities.

We are extremely excited by this next stage in the company’s development as we apply our disruptive technologies to develop improved, minimally invasive diagnostic and prognostic tests for accurate and early detection of cancer and other diseases.”

Chesterford Research Park’s low-density development, set within 250 acres of impressive parkland, offers not only ultra modern and energy efficient laboratory and office space, but also central ‘hub’ facilities within The Nucleus building — which includes a restaurant, café bar, health and fitness centre and meeting and conferencing space. The Park provides an innovative, flexible and future proofed environment for both established and early stage biotechnology and pharmaceutical research and development companies. Cambridge Epigenetix joins major players such as AstraZeneca, Illumina Inc and Domainex, who have also chosen Chesterford as the base from which to advance their research and development.

Notes to Editors

Media enquiries:

Lorna Cuddon
Zyme Communications
E-mail: lorna.cuddon@zymecommunications.com
Phone: +44 (0)7811 996 942

About Cambridge Epigenetix

Cambridge Epigenetix’ mission is to harness the power of epigenetics to develop the next generation of diagnostics and therapeutics. Cambridge Epigenetix utilises innovative technologies, often based on fundamental chemistry, to detect the epigenetic biomarkers that will be most useful in clinical settings. Spun-out of the University of Cambridge in 2012, the Company was founded by Professor Sir Shankar Balasubramanian (co-inventor of Solexa sequencing) and Dr Bobby Yerramilli-Rao to commercialise its founding technology, oxidative bisulfite sequencing (oxBS-Seq), which enables users to quantify, and discriminate between, functionally-distinct DNA modifications – impossible with traditional bisulfite methods. Cambridge Epigenetix is a privately held company headquartered in Cambridge, UK, supported by several high-profile investors: GV (Google Ventures), Sequoia, Syncona, New Science Ventures and the University of Cambridge. The Company is seeking partnerships across a broad range of applications in life sciences, as well as developing its own pipeline.

For more information, visit www.cambridge-epigenetix.com.

About Chesterford Research Park

Chesterford Research Park has proven an ideal environment for life science companies to grow and prosper. Leading bioscience names that have located at Chesterford include Arecor, Charles River Laboratories, Diagnostics for the Real Word (DRW) and Isogenica.  The attractive 250-acre, low-density development is located close to Cambridge and the M11 with London just one hour away by train from nearby Audley End station, ensuring occupiers and visitors enjoy convenient and easy access. Stansted Airport is just 20 minutes’ drive away. Chesterford Research Park is being developed by The Churchmanor Estates Company Plc and is owned by Aviva Investors and Aspire Ltd.

To find out more, visit www.chesterfordresearchpark.com.